Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 15, 2018- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients - CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress
15 Jun 2018 LISBON, Portugal – 15 June 2018 – Global biotherapeutics leader CSL Behring today announced that it will participate in the 4th Congress of the European Academy of Neurology (EAN)...
-
Jun 1, 2018
$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2018 - Australia’s best and brightest biomedical researchers are invited to apply for one of two...
-
May 31, 2018• IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions • New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
31 May 2018 KING OF PRUSSIA, Pa. – 31 May 2018 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved a 3500 IU (international...
-
May 23, 2018
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to develop and commercialise CR845/difelikefalin injection worldwide except in the US, Japan and South Korea for the treatment of chronic kidney...
-
May 18, 2018
CSL Limited today announced a revised profit outlook for fiscal 2018. CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a revised profit outlook for fiscal 2018. The Company now expects net...
-
May 15, 2018
All proposals of the Board of Directors approved by shareholders Election of Jacques Theurillat to the Board of Directors Re-election of standing members of the Board of Directors Dividend of CHF...
-
May 14, 2018HANJ President David Lechner presented the award to Perreault at the association’s 38th Annual Testimonial Dinner Dance
14 May 2018 East Brunswick, N.J. – May 14, 2018 – CEO and Managing Director of CSL Limited Paul Perreault has been named “Humanitarian Man of the Year” by the Hemophilia Association of New...
-
Apr 26, 2018Five patient advocacy organizations are awarded LEAD Grants to support their advocacy initiatives in 2018
26 Apr 2018 KING OF PRUSSIA, Pa. – April 26, 2018 – Patient advocacy groups in Michigan, Washington, Illinois, Missouri and South Carolina are preparing to meet the many challenges standing...
-
Apr 20, 2018- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM
- Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms - CSL Behring is now the only company to offer a portfolio of...
-
Apr 17, 2018
The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management...
-
Apr 12, 2018CSL Behring Marks World Hemophilia Day by Shipping IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia
12 Apr 2018 MONTREAL and KING OF PRUSSIA, Pa. – April 12, 2018 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has...
-
Apr 12, 2018
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older...
-
Mar 29, 2018
Jacques Theurillat to be proposed to Annual Shareholder Meeting for appointment to Board Marc de Garidel will not stand for re-election All other members of the Board of Directors will stand for...
-
Mar 23, 2018
23 Mar 2018 KING OF PRUSSIA, Pa. – March 23, 2018 – CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Mar 20, 2018Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth
20 Mar 2018 KING OF PRUSSIA, Pa. – March 20, 2018 – Forbes has named global biotechnology leader CSL Limited among the world’s Top 50 employers, landing at no. 42 in the business media’s...
-
Mar 17, 2018
Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan Potential of Veltassa® further validated with expansion into Japanese market Deal expands cardio-renal network...
-
Mar 16, 2018First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
16 Mar 2018 KING OF PRUSSIA, Pa. – March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune...
-
Mar 15, 2018
IN 2017 VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH-DRIVERS AND THE SUCCESSFUL DIVESTITURE OF ITS NON-CORE WHOLESALE/RETAIL PHARMACY...
-
Mar 15, 2018First and only subcutaneous immunoglobulin approved for the treatment of CIDP, based on findings from the largest controlled clinical CIDP study
15 Mar 2018 HATTERSHEIM, Germany – 15 March 2018 – Global biotherapeutics leader CSL Behring today announced that the European Commission (EC) has granted marketing authorization for...
-
Mar 15, 2018Life Sciences Pennsylvania recognized CSL Behring’s commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder
15 Mar 2018 KING OF PRUSSIA, Pa. – March 15, 2018 – Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body,...
-
Mar 13, 2018- Industry’s role in ensuring access to medicine is an imperative, not an afterthought - Patient engagement is a key driver to strengthen access
13 Mar 2018 BARCELONA, SPAIN – March 13, 2018 – In a keynote address on patients’ access to medicines at the eyeforpharma Barcelona summit, CSL Chief Executive Officer and Managing Director...
-
Mar 8, 2018
Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update effective immediately in the US THE UNITED STATES (US) FOOD AND DRUG ADMINISTRATION (FDA) HAS...
-
Feb 8, 2018
VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...
-
Jan 4, 2018
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...
-
Jan 4, 2018
Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...